Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells

Li, Haoshan; Zhou, Yan; Cheng, Hongyan; Tian, Jie; Yang, Shao-Qin

doi:10.1016/j.yexmp.2020.104481

Cited by 17 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As demonstrated by the dual-luciferase reporter gene assay, miR-200c could target transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2). Elevated TMPO-AS1 expression activated the mRNA expression of TMEFF2 and coactivated the PI3-K/Akt signaling pathway through targeting miR-200c, thus inhibited drug resistance and metastasis (Li et al, 2020a). TMPO-AS1 was also upregulated in ovarian cancer tissues and cell lines in the study of Zhao et al They validated that increased TMPO-AS1 activates the expression of lipocalin-2 (LCN2) through binding to E2F transcription factor 6 (E2F6).…”

Section: Breast Cervical and Ovarian Cancersmentioning

confidence: 98%

“…LncRNAs are also involved in DNA repair, cell proliferation, and EMT through regulating the expression of various genes linked to carcinogenesis and tumor progression. TMPO-AS1 was demonstrated to have abnormal expression in breast cancer (Mitobe et al, 2020), cervical cancer (Zhao et al, 2020), and ovarian cancers (Li et al, 2020a). In triple-negative breast cancer, the upregulation of TMPO-AS1 was associated with tumor proliferation-related biomarkers.…”

Section: Breast Cervical and Ovarian Cancersmentioning

confidence: 99%

“…TMPO-AS1 was reported to be significantly upregulated in various cancers, such as lung cancer (Yu et al, 2020), breast cancer (Mitobe et al, 2020), colorectal cancer (CRC) (Mohammadrezakhani et al, 2020), hepatocellular carcinoma (HCC) (Liu and Shen, 2020;Wang et al, 2020), gastric cancer (GC) (Sun and Han, 2020), bladder cancer (He et al, 2020b), laryngeal squamous cell carcinoma (LSCC) (Zhang et al, 2020b), ovarian cancer (Li et al, 2020a;Zhao et al, 2020), thyroid cancer (Li et al, 2020b), esophageal cancer (Gao et al, 2020), Wilms tumor (Zhang et al, 2020a), cervical cancer (Gang et al, 2020), retinoblastoma (Peng et al, 2020), osteosarcoma (Cui and Zhao, 2020), or prostate cancer (Huang et al, 2018), and functions as an oncogene in carcinogenesis and tumor progression. To further investigate the aberrant expression of TMPO-AS1 in various cancers and their associated prognosis, this study applied the Gene Expression Profiling Interactive Analysis (GEPIA) online data analysis tool (Tang et al, 2017).…”

Section: Tmpo-as1 Functions As Oncogenic Lncrna In Various Cancersmentioning

confidence: 99%

See 2 more Smart Citations

The Emerging Role of Thymopoietin-Antisense RNA 1 as Long Noncoding RNA in the Pathogenesis of Human Cancers

Zheng

Jia

Zhou

et al. 2021

DNA and Cell Biology

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) play essential roles in the occurrence and development of multiple human cancers. An accumulating body of researches have investigated thymopoietin antisense RNA 1 (TMPO-AS1) as a newly discovered lncRNA, which functions as an oncogenic lncRNA that is upregulated in various human malignancies and associated with poor prognosis. Many studies have detected abnormally high expression levels of TMPO-AS1 in multiple cancers, such as lung cancer, breast cancer, colorectal cancer (CRC), hepatocellular carcinoma, CRC, gastric cancer, ovarian cancer, thyroid cancer, esophageal cancer, Wilms tumor, cervical cancer, retinoblastoma, bladder cancer, osteosarcoma, and prostate cancer. TMPO-AS1 has been subsequently demonstrated to play a pivotal role in tumorigenesis and progression. The aberrantly expressed TMPO-AS1 acts as a competing endogenous RNA (ceRNA) that inhibits miRNA expression, thus activating the expression of downstream oncogenes. This study comprehensively summarizes the aberrant expressions of TMPO-AS1 as reported in the current literature and explains the relevant biological regulation mechanisms in carcinogenesis and tumor progression. Corresponding studies have indicated that TMPO-AS1 has a potential value as a promising biomarker or a target for cancer therapy.

show abstract

Section: Breast Cervical and Ovarian Cancersmentioning

confidence: 98%

Section: Breast Cervical and Ovarian Cancersmentioning

confidence: 99%

Section: Tmpo-as1 Functions As Oncogenic Lncrna In Various Cancersmentioning

confidence: 99%

See 1 more Smart Citation

The Emerging Role of Thymopoietin-Antisense RNA 1 as Long Noncoding RNA in the Pathogenesis of Human Cancers

Zheng

Jia

Zhou

et al. 2021

DNA and Cell Biology

View full text Add to dashboard Cite

show abstract

“…Stimulation of EMT is often associated with one way or another of inhibition of E-cadherin expression or with activation of the Hippo pathway through YAP1, as well as with regulation of the PI3K/AKT pathway. LncRNA-ROR FLNB (filamin B) [168] TMPO-AS1 TMEFF2 (transmembrane protein with EGF like and two follistatin-like domains) [174] Resistance to chemotherapy is associated with the regulation of the expression of proteins (from Tables 1-4) belonging to cell transporters (ABCC1 [136] and ABCB1 [176]), directly affecting the EMT transition (ZEB1 [150]), and affecting key pathways associated with the development of OvCa and EMT. An example of the latter is the SIRT1 protein [119], which inhibits the activity of p53 and associated apoptosis.…”

Section: Pathway Lncrnas and Target Proteins *mentioning

confidence: 99%

LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms

Брага

Фридман

Moscovtsev

et al. 2020

IJMS

163

103

View full text Add to dashboard Cite

Ovarian cancer (OvCa) develops asymptomatically until it reaches the advanced stages with metastasis, chemoresistance, and poor prognosis. Our review focuses on the analysis of regulatory long non-coding RNAs (lncRNAs) competing with protein-coding mRNAs for binding to miRNAs according to the model of competitive endogenous RNA (ceRNA) in OvCa. Analysis of publications showed that most lncRNAs acting as ceRNAs participate in OvCa progression: migration, invasion, epithelial-mesenchymal transition (EMT), and metastasis. More than 30 lncRNAs turned out to be predictors of survival and/or response to therapy in patients with OvCa. For a number of oncogenic (CCAT1, HOTAIR, NEAT1, and TUG1 among others) and some suppressive lncRNAs, several lncRNA/miRNA/mRNA axes were identified, which revealed various functions for each of them. Our review also considers examples of alternative mechanisms of actions for lncRNAs besides being ceRNAs, including binding directly to mRNA or protein, and some of them (DANCR, GAS5, MALAT1, and UCA1 among others) act by both mechanisms depending on the target protein. A systematic analysis based on the data from literature and Panther or KEGG (Kyoto Encyclopedia of Genes and Genomes) databases showed that a significant part of lncRNAs affects the key pathways involved in OvCa metastasis, EMT, and chemoresistance.

show abstract

“…Moreover, it activates the PI3K/Akt signaling pathway. TMPO-AS1 silencing has suppressed epithelial-mesenchymal transition (EMT), invasiveness, migration and 5-FU resistance in ovarian cancer cells (142). Table 7 summarizes the role of lnRNAs in modulation of response to 5-FU in other cancers.…”

Section: Lncrnas and Response To 5-fumentioning

confidence: 99%

5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent

et al. 2021

View full text Add to dashboard Cite

5-fluorouracil (5-FU) is among the mostly administrated chemotherapeutic agents for a wide variety of neoplasms. Non-coding RNAs have a central impact on the determination of the response of patients to 5-FU. These transcripts via modulation of cancer-related pathways, cell apoptosis, autophagy, epithelial–mesenchymal transition, and other aspects of cell behavior can affect cell response to 5-FU. Modulation of expression levels of microRNAs or long non-coding RNAs may be a suitable approach to sensitize tumor cells to 5-FU treatment via modulating multiple biological signaling pathways such as Hippo/YAP, Wnt/β-catenin, Hedgehog, NF-kB, and Notch cascades. Moreover, there is an increasing interest in targeting these transcripts in various kinds of cancers that are treated by 5-FU. In the present article, we provide a review of the function of non-coding transcripts in the modulation of response of neoplastic cells to 5-FU.

show abstract

Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells

Cited by 17 publications

References 29 publications

The Emerging Role of Thymopoietin-Antisense RNA 1 as Long Noncoding RNA in the Pathogenesis of Human Cancers

The Emerging Role of Thymopoietin-Antisense RNA 1 as Long Noncoding RNA in the Pathogenesis of Human Cancers

LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms

5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent

Contact Info

Product

Resources

About